Enclomiphene Citrate Medicare Part D Coverage

Why Medicare Part D Does Not Cover Enclomiphene Citrate

Medicare Part D covers outpatient prescription drugs that carry FDA approval and appear on a plan's formulary. Enclomiphene citrate meets neither criterion. The drug has never received standalone approval from the FDA, despite multiple clinical trials conducted by Repros Therapeutics (now Allergan) between 2009 and 2016 [1]. Part D plans are prohibited by CMS regulations from covering compounded medications unless no commercially available alternative exists for the patient's condition [2].

Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that the FDA approved in 1967 under the brand name Clomid. Standard clomiphene contains roughly a 62:38 mixture of enclomiphene to zuclomiphene [3]. The zuclomiphene isomer has a longer half-life (approximately 30 days vs. 10 hours for enclomiphene) and carries estrogenic agonist activity that some clinicians believe contributes to side effects like visual disturbances and mood changes.

Because the FDA considers enclomiphene an unapproved new molecular entity rather than a generic version of clomiphene, compounding pharmacies produce it under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. This regulatory classification places it permanently outside the Medicare Part D benefit structure.

The Endocrine Society's 2018 guidelines on testosterone therapy acknowledge clomiphene citrate as an off-label option for secondary hypogonadism in men seeking fertility preservation, though the guidelines do not specifically endorse the isolated enclomiphene isomer [4]. This distinction matters: Medicare Part D could theoretically cover clomiphene citrate (Clomid) if a Part D plan chose to include it, but the compounded single-isomer product remains ineligible regardless.

The Regulatory Gap: What Happened to FDA Approval

Repros Therapeutics submitted two Phase III trials, ZA-301 and ZA-302, seeking FDA approval for enclomiphene citrate under the brand name Androxal. Both trials enrolled men with secondary hypogonadism and demonstrated that enclomiphene 12.5 mg and 25 mg daily raised total testosterone into the normal range (300 to 1,000 ng/dL) in over 75% of participants while preserving or improving sperm concentration [5]. In ZA-301 (N=302), 87.2% of men on enclomiphene 12.5 mg achieved normal testosterone at 12 months compared to 36.7% on topical testosterone gel, which suppressed sperm counts.

The FDA issued a Complete Response Letter in 2015, requesting additional data on luteinizing hormone (LH) suppression and long-term cardiovascular safety. Repros ultimately abandoned the application. No other company has since filed a New Drug Application for enclomiphene.

This regulatory limbo created the current access challenge. "Enclomiphene sits in a category of drugs that have strong Phase III data but no commercial sponsor willing to invest in the remaining regulatory requirements," noted Dr. Mohit Khera, a urologist at Baylor College of Medicine, in a 2023 commentary on male hypogonadism treatment options [6]. Without an NDA holder, no manufacturer can negotiate formulary placement with Medicare Part D plans or private insurers.

What Enclomiphene Citrate Costs Without Insurance

The average compounded price for enclomiphene citrate runs approximately $90 per month, though actual costs range from $60 to $120 depending on the compounding pharmacy, the prescribed dose, and whether the patient orders through a telehealth platform [7].

Price variation depends on several factors. A 503B outsourcing facility that produces enclomiphene in bulk batches can offer lower per-unit costs than a traditional 503A pharmacy compounding individual prescriptions. Geographic location also affects pricing: pharmacies in states with higher overhead (New York, California) tend to charge $10 to $20 more per month than those in lower-cost regions.

For comparison, generic clomiphene citrate (the combined isomer product) costs between $10 and $30 for a 30-day supply at most retail pharmacies when using a discount card [8]. Some patients and prescribers opt for standard clomiphene as a cost-saving measure, accepting the presence of the zuclomiphene isomer rather than paying the compounding premium.

A breakdown of typical monthly costs:

• Enclomiphene 12.5 mg daily (compounded): $60 to $90
• Enclomiphene 25 mg daily (compounded): $80 to $120
• Clomiphene citrate 25 mg daily (generic, retail pharmacy): $10 to $30
• Clomiphene citrate 50 mg every other day (generic, retail pharmacy): $10 to $25

Medicare beneficiaries who choose enclomiphene will pay these cash prices entirely out of pocket. The expense does not count toward Part D's True Out-of-Pocket (TrOOP) threshold or catastrophic coverage limit since it falls outside the Part D benefit.

How to Get Enclomiphene Citrate at the Lowest Price

Several strategies can reduce what you pay for compounded enclomiphene. None involve Medicare, but each addresses a different barrier.

Telehealth subscription platforms. Companies that specialize in men's health or hormone optimization frequently bundle the prescriber visit, lab work, and compounded medication into a single monthly fee. Total costs through these platforms typically fall between $75 and $150 per month, which can be competitive with paying separately for a clinic visit, lab draw, and pharmacy fill. The convenience factor also reduces missed appointments and treatment gaps.

Compounding pharmacy discount programs. Some 503B outsourcing facilities offer loyalty pricing or multi-month supply discounts. Ordering a 90-day supply rather than a 30-day fill can reduce per-month costs by 15% to 25% at certain pharmacies.

HSA and FSA accounts. Because enclomiphene requires a prescription, it qualifies as an eligible medical expense under IRS rules for Health Savings Accounts and Flexible Spending Accounts [9]. Medicare beneficiaries who have an HSA from a prior high-deductible health plan can use remaining funds, though active Medicare enrollment typically disqualifies new HSA contributions.

Switching to generic clomiphene citrate. The American Urological Association's 2024 guideline on male infertility lists clomiphene citrate (not enclomiphene specifically) as an option for men with hypogonadotropic hypogonadism who wish to maintain spermatogenesis [10]. For patients whose primary goal is testosterone optimization with fertility preservation, standard clomiphene at $10 to $30 per month through a Part D plan or retail discount card may achieve comparable results.

Dr. Larry Lipshultz, former chief of the Division of Male Reproductive Medicine at Baylor College of Medicine, has stated: "Clomiphene citrate remains an effective off-label choice for secondary hypogonadism. The isolated trans-isomer may offer a cleaner side-effect profile, but many patients respond well to the racemic mixture at a fraction of the cost" [11].

Enclomiphene vs. Clomiphene: The Clinical Difference That Drives Cost

The rationale for choosing compounded enclomiphene over generic clomiphene centers on the zuclomiphene isomer's pharmacokinetics. Zuclomiphene accumulates in tissue due to its long half-life, acting as an estrogen receptor agonist in some contexts. In the ZA-302 trial (N=242), men taking enclomiphene 12.5 mg reported lower rates of hot flashes (2.1% vs. 5.8% with combined clomiphene) and visual disturbances (0.8% vs. 3.3%) [5].

A 2019 retrospective analysis of 172 men treated at a single men's health clinic found that those switched from clomiphene to enclomiphene reported a 40% reduction in estrogen-related side effects (mood swings, nipple tenderness, and visual changes) while maintaining equivalent total testosterone levels averaging 548 ng/dL [12]. The study was not randomized, however, and the placebo effect of switching medications cannot be discounted.

For Medicare beneficiaries weighing the cost-benefit calculation, the key question is whether the tolerability advantage of pure enclomiphene justifies $60 to $90 more per month than generic clomiphene. Patients who tolerate standard clomiphene without significant side effects may find no clinical reason to pay the premium. Those experiencing zuclomiphene-related adverse effects have a concrete reason to prefer the single-isomer product despite the out-of-pocket burden.

Medicare Advantage and Supplemental Plans: Do They Help?

Medicare Advantage (Part C) plans include Part D drug coverage within their benefit package, but they follow the same CMS formulary rules. No Medicare Advantage plan covers compounded enclomiphene citrate [2].

Medicare Supplement (Medigap) plans also provide no pathway to coverage. Medigap policies cover cost-sharing for Medicare-approved services. Since original Medicare does not approve enclomiphene, Medigap has nothing to supplement.

One narrow exception exists for Medicare beneficiaries with employer-sponsored retiree drug plans. These plans sometimes operate outside standard Part D formulary restrictions. A small number of employer plans with custom pharmacy benefits have covered compounded medications on a case-by-case basis, though enclomiphene specifically would still require prior authorization and a determination that no commercially available alternative is appropriate [13]. This pathway is uncommon and depends entirely on the employer plan's benefit design.

State Pharmaceutical Assistance Programs and Other Safety Nets

Twenty-three states and the U.S. Virgin Islands operate State Pharmaceutical Assistance Programs (SPAPs) that help Medicare beneficiaries with drug costs [14]. These programs vary widely in eligibility criteria, covered drugs, and benefit levels. Because SPAPs generally coordinate with Medicare Part D and follow similar formulary logic, compounded medications like enclomiphene typically fall outside their scope.

Patient assistance programs (PAPs) run by pharmaceutical manufacturers also offer no help here. PAPs exist for branded, FDA-approved medications. Enclomiphene has no NDA holder and no manufacturer-sponsored assistance program.

The most realistic financial safety nets for Medicare beneficiaries seeking enclomiphene are:

• Using existing HSA/FSA balances for the compounding pharmacy cost
• Requesting generic clomiphene citrate through Part D as a lower-cost alternative
• Enrolling in a telehealth platform that negotiates bulk compounding pricing
• Asking the compounding pharmacy about multi-month supply discounts

What to Ask Your Prescriber Before Starting Enclomiphene

A prescriber evaluation should address several clinical and financial questions before committing to compounded enclomiphene over alternatives covered by Medicare Part D.

First, confirm the diagnosis. The Endocrine Society recommends diagnosing male hypogonadism only when morning total testosterone falls below 300 ng/dL on at least two separate measurements, combined with consistent signs and symptoms [4]. A single low reading is not sufficient for diagnosis.

Second, discuss whether standard clomiphene citrate might work. If you have never tried the generic product, starting with a 25 mg daily dose of clomiphene for 8 to 12 weeks provides a low-cost trial period. Check a follow-up testosterone level and estradiol level at 6 to 8 weeks. If testosterone normalizes and side effects are minimal, the switch to compounded enclomiphene may be unnecessary.

Third, evaluate fertility goals. Men who do not need to preserve fertility have additional options, including testosterone cypionate injections ($30 to $80 per month through Part D for generic formulations) or transdermal testosterone gel. These FDA-approved products appear on most Part D formularies and carry lower out-of-pocket costs for Medicare beneficiaries [15].

Fourth, request baseline labs: total testosterone, free testosterone, LH, FSH, estradiol, prolactin, CBC, and a comprehensive metabolic panel. Follow-up monitoring every 3 to 6 months on therapy should include at minimum total testosterone and a CBC to monitor for polycythemia, which occurs in approximately 3% to 5% of men on SERM therapy [4].

The Future of Enclomiphene Coverage

Several developments could change the coverage picture for enclomiphene in the coming years. At least two pharmaceutical companies have expressed interest in pursuing FDA approval for single-isomer clomiphene products, though neither has publicly filed an IND application as of May 2026. If enclomiphene receives FDA approval, it would become eligible for Part D formulary inclusion, though the branded price would likely exceed current compounding costs until generic entry.

The FDA's increased scrutiny of compounding pharmacies under the Drug Quality and Security Act could also affect availability. In 2024, the FDA issued warning letters to several compounding facilities producing peptides and hormonal products, though enclomiphene has not been specifically targeted [16]. Any future enforcement action against enclomiphene compounding could reduce supply and increase prices.

CMS has also explored expanding the definition of Part D-eligible drugs in proposed rulemaking, though compounded products remain excluded under current statutory language. Legislative change at the congressional level would be required to bring compounded drugs into Part D, and no active bill addresses this gap as of 2026.

For now, Medicare beneficiaries who need enclomiphene should plan for ongoing out-of-pocket costs and work with their prescriber to optimize the treatment regimen for both clinical outcomes and affordability. Monitoring testosterone levels at 3-month intervals allows dose adjustments that may reduce the required supply and lower monthly costs by 20% to 30% for patients who respond to the 12.5 mg dose rather than 25 mg.